HE4和CA125联合检测在上皮性卵巢癌风险评估中的应用

The Value of ROMA Obtained by HE4 and CA125 Serum Levels on the Risk Assessment of Ovarian Cancer

目的探讨人附睾上皮分泌蛋白4(HE4)与CA125联合检测在卵巢癌风险评估中的应用价值。方法用ELISA法检测上皮性卵巢癌、妇科良性病变、其他妇科恶性肿瘤及其他系统恶性肿瘤共84例女性患者血清HE4和CA125水平,计算出卵巢恶性肿瘤风险值(ROMA值),联合绝经状态评估患卵巢癌的风险性。结果由ROMA值结合绝经状态在84例患者中诊断出卵巢癌的敏感度和特异度分别为66.7%和91.7%,均高于单一CA125检测诊断出卵巢癌的敏感度(50.0%)和特异度(75.0%),差异有统计学意义(P<0.05)。结论根据HE4和CA125结果结合绝经状态计算卵巢恶性肿瘤风险值(ROMA值),在诊断卵巢癌的敏感度和特异度均高于单一CA125检测,有助于卵巢癌的诊断和疗效监测。

Objective To evaluate ROMA（risk of ovarian malignancy algorithm） obtained by human epididymis protein 4（HE4）and CA125 serum levels on the risk assessment of ovarian cancer.Methods HE4 and CA125 were determined by ELISA in ovarian cancer patients,gynecological benign disease patients,other gynecological tumor patients and other organ cancer patients（total n=84）.ROMA was calculated by HE4 and CA125 levels combined with menopause state to analyze the risk of ovarian cancer.Results The sensitivity and specificity of ROMA to diagnose ovarian cancer from 84 patients combined with menopause state were 66.7% and 91.7%,respectively,but the sensitivity and specificity of CA125 levels were lower,50% and 75%,respectively.There was statistically significant difference（P0.05）.Conclusion ROMA determination is helpful in the diagnosis and prognosis of ovarian cancer.